MX2009003772A - Formulaciones de oximorfona robustas, de liberacion sostenida. - Google Patents
Formulaciones de oximorfona robustas, de liberacion sostenida.Info
- Publication number
- MX2009003772A MX2009003772A MX2009003772A MX2009003772A MX2009003772A MX 2009003772 A MX2009003772 A MX 2009003772A MX 2009003772 A MX2009003772 A MX 2009003772A MX 2009003772 A MX2009003772 A MX 2009003772A MX 2009003772 A MX2009003772 A MX 2009003772A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained release
- release formulations
- oxymorphone
- formulations
- robust
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proveen formulaciones robustas de liberación sostenida, formas de dosis sólidas que comprenden las formulaciones robustas de liberación sostenida, y métodos para preparar y usar esas formulaciones y esas formas de dosis sólidas. La robustez de la formulación de liberación sostenida está relacionada con el tamaño de partícula de la goma hidrófila. Las formulaciones de liberación sostenida resisten el vaciado de la dosis cuando se ingieren con alcohol. Las formulaciones son útiles para el tratamiento de un paciente de sufre de una condición, por ejemplo, de dolor. Las formulaciones comprenden por lo menos un fármaco. En una modalidad, el fármaco es un opioide, por ejemplo, oximorfona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2006/039767 WO2008045046A1 (en) | 2006-10-10 | 2006-10-10 | Robust sustained release formulations of oxymorphone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009003772A true MX2009003772A (es) | 2009-07-22 |
Family
ID=38169509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009003772A MX2009003772A (es) | 2006-10-10 | 2006-10-10 | Formulaciones de oximorfona robustas, de liberacion sostenida. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2097069A1 (es) |
| JP (1) | JP2010505947A (es) |
| KR (1) | KR20090076946A (es) |
| CN (1) | CN101578095A (es) |
| AU (1) | AU2006349471A1 (es) |
| BR (1) | BRPI0621952A2 (es) |
| CA (1) | CA2652980A1 (es) |
| IL (1) | IL198169A0 (es) |
| MX (1) | MX2009003772A (es) |
| WO (1) | WO2008045046A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1551770A (zh) | 2001-07-06 | 2004-12-01 | ������ҩ������˾ | 羟吗啡酮控释制剂 |
| JP2010505948A (ja) * | 2006-10-10 | 2010-02-25 | ペンウェスト ファーマシューティカルズ カンパニー | オキシモルフォンのロバスト性持続放出製剤およびその使用方法 |
| EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1551770A (zh) * | 2001-07-06 | 2004-12-01 | ������ҩ������˾ | 羟吗啡酮控释制剂 |
| BR0205722A (pt) * | 2001-07-06 | 2005-04-05 | Penwest Pharmaceuticals Compan | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor |
| CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
| JP2010505948A (ja) * | 2006-10-10 | 2010-02-25 | ペンウェスト ファーマシューティカルズ カンパニー | オキシモルフォンのロバスト性持続放出製剤およびその使用方法 |
-
2006
- 2006-10-10 EP EP06816745A patent/EP2097069A1/en not_active Withdrawn
- 2006-10-10 AU AU2006349471A patent/AU2006349471A1/en not_active Abandoned
- 2006-10-10 MX MX2009003772A patent/MX2009003772A/es not_active Application Discontinuation
- 2006-10-10 BR BRPI0621952-7A patent/BRPI0621952A2/pt not_active Application Discontinuation
- 2006-10-10 CN CNA2006800560524A patent/CN101578095A/zh active Pending
- 2006-10-10 KR KR1020097008716A patent/KR20090076946A/ko not_active Application Discontinuation
- 2006-10-10 CA CA002652980A patent/CA2652980A1/en not_active Abandoned
- 2006-10-10 WO PCT/US2006/039767 patent/WO2008045046A1/en active Application Filing
- 2006-10-10 JP JP2009532329A patent/JP2010505947A/ja active Pending
-
2009
- 2009-04-16 IL IL198169A patent/IL198169A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090076946A (ko) | 2009-07-13 |
| JP2010505947A (ja) | 2010-02-25 |
| CA2652980A1 (en) | 2008-04-17 |
| BRPI0621952A2 (pt) | 2011-10-18 |
| EP2097069A1 (en) | 2009-09-09 |
| AU2006349471A1 (en) | 2008-04-17 |
| CN101578095A (zh) | 2009-11-11 |
| WO2008045046A1 (en) | 2008-04-17 |
| IL198169A0 (en) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009003771A (es) | Formulaciones robustas de liberacion sostenida. | |
| MX2008011823A (es) | Forma de dosificacion solida que contiene un agente activo de sabor encubierto. | |
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| WO2007095600A3 (en) | Disintegrable oral films | |
| WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
| NO20070887L (no) | Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet | |
| WO2007103293A3 (en) | Ethanol-resistant sustained release formulations | |
| WO2008085765A3 (en) | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | |
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| WO2007053698A3 (en) | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms | |
| MX2010000803A (es) | Formulaciones de analgesicos no opioides y opioides confinados. | |
| WO2010062688A3 (en) | Dosage form for insertion into the mouth | |
| WO2007143155A3 (en) | Sustained release pharmaceutical dosage form containing phenylephrine | |
| NZ592276A (en) | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID | |
| MX2008000099A (es) | Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones. | |
| IL220722A (en) | Use of fentanyl for the preparation of a rapid-release pharmacological preparation for eruptive pain and a biodegradable device for providing the mucosal pathway that is suitable for direct delivery through the mantle of the fentile | |
| UA104745C2 (ru) | Оральная фармацевтическая дозированная форма, защищенная от несанкционированного использования, содержащая опиоидный анальгетик | |
| MX2013009773A (es) | Vehiculo masticable para absorcion bucal. | |
| IL179896A (en) | Opioid with a delayed oral dosage form containing a mixture of opioid agonist and antagonist for use in the treatment of nervous leg syndrome | |
| JP2009522376A5 (es) | ||
| WO2007106550A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
| NZ628513A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| WO2007018588A8 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
| WO2007146805A3 (en) | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty | |
| WO2008106689A3 (en) | Breakthrough pain management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |